Skip to content

Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium

Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06253000
Enrollment
158
Registered
2024-02-12
Start date
2023-06-10
Completion date
2026-12-30
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Cerebrovascular Accident, Atrial Fibrillation Recurrent, Death, Stroke, Transient Ischemic Attack

Keywords

atrial fibrillation, radiofrequency ablation, cryoablation, left atrium, the posterior wall of the left atrium, atrial remodeling

Brief summary

Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times. The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA). The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.

Interventions

PROCEDURECryoablation

Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.

PROCEDURERadiofrequency ablation

Radiofrequency ablation of pulmonary veins according to the "box isolation" type using a non-fluoroscopic navigation system.

Sponsors

Bakulev Scientific Center of Cardiovascular Surgery
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

A randomized double-blind controlled trial in two groups

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age over 18 years old; * Atrial fibrillation resistant to antiarrhythmic therapy; * Persistent and long-persisting form of atrial fibrillation; * The patient's consent to participate in the study.

Exclusion criteria

* Age under 18 and over 80 years old; * The presence of another cardiac pathology requiring surgical treatment; * Congenital heart defects; * Previous "open" cardiac surgery; * Bone marrow diseases; * Pathology of the blood coagulation system; * The left ventricular ejection fraction is less than 40%; * Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min); * Drug-resistant hypertension (despite hypotensive therapy); * Organically altered mitral valve; * There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; * The patient's participation in another clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Cerebral eventsFrom the date of ablation until the date of the event, assessed up to 24 months.The number of patients who had a stroke or acute cerebrovascular accident or a transient ischemic attack within 24 months after ablation.

Secondary

MeasureTime frameDescription
Hospital mortalityFrom the date of ablation until the date of death, assessed up to 5 days.The number of patients who died in the hospital.
Non-lethal eventsFrom the date of ablation to the date of any of the listed events, assessed up to 5 days.Number of participants with non-lethal events. The main hospital non-lethal events (bleeding, tamponade, perforation of the walls of the heart, damage to the esophagus).
Recurrence of AFFrom the date of ablation until the date of recurrent atrial fibrillation, assessed up to 24 months.The number of patients with recurrent atrial fibrillation after surgery.
Long-term mortalityFrom the date of ablation until the date of death, assessed up to 24 months.The number of patients who died during the follow-up period.

Countries

Russia

Contacts

CONTACTAndrey Filatov
agfilatov@bakulev.ru+7(495) 414-77-02
PRINCIPAL_INVESTIGATORAndrey Filatov

Bakulev Scientific Center for Cardiovascular Surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026